pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

18,993 catalysts · 18,987 approval · 7,115 phase readout · 5,000 device 510k · 4,728 grant · 3,590 8k filing · 2,000 device pma

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 17 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 1 catalyst2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts2026-11-09: 1 catalyst2026-11-10: 0 catalysts2026-11-11: 0 catalysts2026-11-12: 0 catalysts2026-11-13: 0 catalysts2026-11-14: 0 catalysts2026-11-15: 0 catalysts2026-11-16: 0 catalysts2026-11-17: 0 catalysts2026-11-18: 0 catalysts2026-11-19: 0 catalysts2026-11-20: 0 catalysts2026-11-21: 0 catalysts2026-11-22: 0 catalysts
view
agendamonth
hide past →
sort
soonestlatesttypesponsoralpha
type: filing×type: approval×clear all
type
  • approval18,987
  • phase readout7,115
  • device 510k5,000
  • grant4,728
  • 8k filing3,590
  • device pma2,000
  • device recall
2,000
  • recall1,126
  • device adverse event1,000
  • earnings585
  • therapy area
    • Ophthalmology5

    Week of Jun 23, 2025

    4
    ›Jun 27, 2025approval428d agoSTELARA (USTEKINUMAB) — FDA approvalustekinumab

    Sponsor: JANSSEN BIOTECH. Form: INJECTABLE. Route: INJECTION

    full page →ustekinumab →fda approvals ↗
    ›Jun 27, 2025approval428d agoGAMIFANT (EMAPALUMAB-LZSG) — FDA approvalSobi Inc

    Sponsor: NOVIMMUNE S.A.. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jun 27, 2025approval428d agoPYZCHIVA (USTEKINUMAB-TTWE) — FDA approvalPYZCHIVA

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTABLE. Route: INJECTION

    full page →PYZCHIVA →fda approvals ↗
    ›Jun 27, 2025approval428d agoULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approvalAlexion Pharmaceuticals Inc

    Sponsor: ALEXION PHARM. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗

    Week of Jun 30, 2025

    3
    ›Jul 1, 2025approval424d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Jul 1, 2025approval

    Week of Jul 7, 2025

    6
    ›Jul 8, 2025approval417d agoELREXFIO (ELRANATAMAB) — FDA approvalelranatamab

    Sponsor: PFIZER INC. Form: SOLUTION. Route: INJECTION

    full page →elranatamab →fda approvals ↗
    ›Jul 9, 2025approval

    Week of Jul 14, 2025

    5
    ›Jul 15, 2025approval410d agoDUREZOL (DIFLUPREDNATE) — FDA approvalDIFLUPREDNATE

    Sponsor: SANDOZ. Form: EMULSION. Route: OPHTHALMIC

    full page →DIFLUPREDNATE →fda approvals ↗
    ›Jul 16, 2025approval

    Week of Jul 21, 2025

    12
    ›Jul 21, 2025approval404d agoNEXLETOL (BEMPEDOIC ACID) — FDA approvalbempedoic acid

    Sponsor: ESPERION THERAPS INC. Form: TABLET. Route: ORAL

    full page →bempedoic acid →fda approvals ↗
    ›Jul 21, 2025approval

    Week of Jul 28, 2025

    16
    ›Jul 28, 2025approval397d agoCOPIKTRA (DUVELISIB) — FDA approvalSecura Bio Inc

    Sponsor: SECURA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jul 29, 2025approval

    Week of Aug 4, 2025

    4
    ›Aug 4, 2025approval390d agoOXYCODONE HYDROCHLORIDE — FDA approvalOXYCODONE HYDROCHLORIDE

    Sponsor: ASCENT PHARMS INC. Form: TABLET. Route: ORAL

    full page →OXYCODONE HYDROCHLORIDE →fda approvals ↗
    ›Aug 5, 2025approval
    ← prev
    page 327 of 380
    next →
    424d ago
    TRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: RUBICON RESEARCH. Form: TABLET. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Jul 3, 2025approval422d agoISTURISA (OSILODROSTAT PHOSPHATE) — FDA approvalosilodrostat phosphate

    Sponsor: RECORDATI RARE. Form: TABLET. Route: ORAL

    full page →osilodrostat phosphate →fda approvals ↗
    416d ago
    SOGROYA (SOMAPACITAN-BECO) — FDA approvalsomatriptan albumin bound LA

    Sponsor: NOVO NORDISK INC. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →somatriptan albumin bound LA →fda approvals ↗
    ›Jul 9, 2025approval416d agoHUMATROPE (SOMATROPIN) — FDA approvalEMD Serono Inc

    Sponsor: LILLY. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jul 10, 2025approval415d agoELREXFIO (ELRANATAMAB) — FDA approvalelranatamab

    Sponsor: PFIZER INC. Form: SOLUTION. Route: INJECTION

    full page →elranatamab →fda approvals ↗
    ›Jul 11, 2025approval414d agoQSYMIA (PHENTERMINE HYDROCHLORIDE) — FDA approval(phentermine hydrochloride + topiramate) ER

    Sponsor: VIVUS LLC. Form: CAPSULE, EXTENDED RELEASE. Route: ORAL

    full page →(phentermine hydrochloride + topiramate) ER →fda approvals ↗
    ›Jul 11, 2025approval414d agoLEVOCETIRIZINE DIHYDROCHLORIDE — FDA approvalLEVOCETIRIZINE DIHYDROCHLORIDE

    Sponsor: MICRO LABS LTD INDIA. Form: TABLET. Route: ORAL

    full page →LEVOCETIRIZINE DIHYDROCHLORIDE →fda approvals ↗
    409d ago
    ROBINUL (GLYCOPYRROLATE) — FDA approvalGLYCOPYRROLATE

    Sponsor: HIKMA. Form: INJECTABLE. Route: INJECTION

    full page →GLYCOPYRROLATE →fda approvals ↗
    ›Jul 16, 2025approval409d agoHUMIRA (ADALIMUMAB) — FDA approvaladalimumab

    Sponsor: ABBVIE INC. Form: VIAL

    full page →adalimumab →fda approvals ↗
    ›Jul 16, 2025approval409d agoDEXTROAMPHETAMINE SULFATE — FDA approvalDEXTROAMPHETAMINE SULFATE

    Sponsor: AZURITY. Form: TABLET. Route: ORAL

    full page →DEXTROAMPHETAMINE SULFATE →fda approvals ↗
    ›Jul 18, 2025approval407d agoZEJULA (NIRAPARIB TOSYLATE) — FDA approvalniraparib

    Sponsor: GLAXOSMITHKLINE. Form: TABLET. Route: ORAL

    full page →niraparib →fda approvals ↗
    404d ago
    NEXLETOL (BEMPEDOIC ACID) — FDA approvalbempedoic acid

    Sponsor: ESPERION THERAPS INC. Form: TABLET. Route: ORAL

    full page →bempedoic acid →fda approvals ↗
    ›Jul 21, 2025approval404d agoNEXLIZET (BEMPEDOIC ACID) — FDA approval(bempedoic acid + ezetimibe)

    Sponsor: ESPERION THERAPS INC. Form: TABLET. Route: ORAL

    full page →(bempedoic acid + ezetimibe) →fda approvals ↗
    ›Jul 21, 2025approval404d agoNEXLIZET (BEMPEDOIC ACID) — FDA approval(bempedoic acid + ezetimibe)

    Sponsor: ESPERION THERAPS INC. Form: TABLET. Route: ORAL

    full page →(bempedoic acid + ezetimibe) →fda approvals ↗
    ›Jul 21, 2025approval404d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Jul 21, 2025approval404d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Jul 22, 2025approval403d agoXYZAL ALLERGY 24HR (LEVOCETIRIZINE DIHYDROCHLORIDE) — FDA approvalSanofi

    Sponsor: CHATTEM SANOFI. Form: SOLUTION. Route: ORAL

    full page →fda approvals ↗
    ›Jul 23, 2025approval402d agoOTEZLA (APREMILAST) — FDA approvalapremilast

    Sponsor: AMGEN INC. Form: TABLET. Route: ORAL

    full page →apremilast →fda approvals ↗
    ›Jul 24, 2025approval401d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Jul 24, 2025approval401d agoHALOPERIDOL DECANOATE — FDA approvalHALOPERIDOL DECANOATE

    Sponsor: MANKIND PHARMA. Form: INJECTABLE. Route: INJECTION

    full page →HALOPERIDOL DECANOATE →fda approvals ↗
    ›Jul 25, 2025approval400d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: ALEMBIC. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jul 25, 2025approval400d agoIBANDRONATE SODIUM — FDA approvalIBANDRONATE SODIUM

    Sponsor: ACCORD HLTHCARE. Form: INJECTABLE. Route: INTRAVENOUS

    full page →IBANDRONATE SODIUM →fda approvals ↗
    396d ago
    AVTOZMA (TOCILIZUMAB-ANOH) — FDA approvalAVTOZMA

    Sponsor: CELLTRION INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →AVTOZMA →fda approvals ↗
    ›Jul 29, 2025approval396d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: PH HEALTH. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jul 29, 2025approval396d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalIGC Pharma, Inc.

    Sponsor: PH HEALTH. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Jul 29, 2025approval396d agoHYRIMOZ (ADALIMUMAB-ADAZ) — FDA approvalHYRIMOZ

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →HYRIMOZ →fda approvals ↗
    ›Jul 30, 2025approval395d agoTRACLEER (BOSENTAN) — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

    Sponsor: ACTELION. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Jul 30, 2025approval395d agoTRACLEER (BOSENTAN) — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

    Sponsor: ACTELION. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Jul 30, 2025approval395d agoACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: CHARTWELL. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Jul 30, 2025approval395d agoACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: CHARTWELL. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Jul 30, 2025approval395d agoACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: CHARTWELL. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Jul 31, 2025approval394d agoSPRAVATO (ESKETAMINE HYDROCHLORIDE) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: SPRAY. Route: NASAL

    full page →fda approvals ↗
    ›Jul 31, 2025approval394d agoLEQVIO (INCLISIRAN SODIUM) — FDA approvalinclisiran

    Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →inclisiran →fda approvals ↗
    ›Aug 1, 2025approval393d agoMETHYLPREDNISOLONE — FDA approvalMEDROL

    Sponsor: SANDOZ. Form: TABLET. Route: ORAL

    full page →MEDROL →fda approvals ↗
    ›Aug 1, 2025approval393d agoMETHYLPREDNISOLONE — FDA approvalMEDROL

    Sponsor: SANDOZ. Form: TABLET. Route: ORAL

    full page →MEDROL →fda approvals ↗
    ›Aug 1, 2025approval393d agoMETHYLPREDNISOLONE — FDA approvalMEDROL

    Sponsor: SANDOZ. Form: TABLET. Route: ORAL

    full page →MEDROL →fda approvals ↗
    ›Aug 1, 2025approval393d agoNURTEC ODT (RIMEGEPANT SULFATE) — FDA approvalrimegepant sulfate ODT

    Sponsor: PFIZER. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →rimegepant sulfate ODT →fda approvals ↗
    389d ago
    DAYBUE (TROFINETIDE) — FDA approvaltrofinetide

    Sponsor: ACADIA PHARMS INC. Form: SOLUTION. Route: ORAL

    full page →trofinetide →fda approvals ↗
    ›Aug 5, 2025approval389d agoDAYBUE (TROFINETIDE) — FDA approvaltrofinetide

    Sponsor: ACADIA PHARMS INC. Form: SOLUTION. Route: ORAL

    full page →trofinetide →fda approvals ↗
    ›Aug 5, 2025approval389d agoPOMALIDOMIDE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: TEVA PHARMS USA. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    $PFE28.03-0.96%
    $BMY67.25-0.48%
    $ESPR
    $NVO47.19-3.02%
    $ESPR
    $ESPR
    $ABBV259.04-1.47%
    $PFE28.03-0.96%
    $ESPR
    $AMGN439.48-0.20%
    $IGC0.2670+0.41%
    $SNY45.01-0.91%
    $IGC0.2670+0.41%
    $NVS157.54-1.53%
    $ACAD29.57-0.04%
    $ACAD29.57-0.04%
    $PFE28.03-0.96%